Trials / Recruiting
RecruitingNCT07264634
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Ascendis Pharma A/S · Industry
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Palopegteriparatide | Palopegteriparatide prescribed as per normal clinical practice |
Timeline
- Start date
- 2026-03-19
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
- First posted
- 2025-12-04
- Last updated
- 2026-04-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07264634. Inclusion in this directory is not an endorsement.